{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:35:41Z","timestamp":1793262941733,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Reported data indicate that cancer cells have increased rates of glucose metabolism, as determined by 18FDG-PET imaging in patients with malignancies. The results of many studies have demonstrated that the expression of glucose transporters, especially Glut-1, is increased in a variety of malignancies. This study was undertaken to assess the differential expression of Glut-1 and Glut-3 by benign and malignant melanocytic lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Immunohistochemical staining for Glut-1 and Glut-3 was performed on paraffin-embedded tissue sections prepared from melanocytic nevi (12 cases), Spitz nevi (12 cases) and primary cutaneous malignant melanomas (20 cases).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We observed immunoreactivity for Glut-1 in all melanocytic nevi, 9 of the 12 Spitz nevi and in 9 of the 20 malignant melanomas, whereas Glut-3 was expressed in all the melanocytic lesions, both benign and malignant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings indicate that the glucose transporters Glut-1 and Glut-3 play a role in the glucose metabolism of melanocytic cells. Glut-1 was present in the majority of benign nevi, whereas its expression was downregulated in 55% of malignant melanomas. Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-9966-27-34","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T06:13:29Z","timestamp":1220422409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions"],"prefix":"10.1186","volume":"27","author":[{"given":"Paola","family":"Parente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Coli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Massi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela M","family":"Fabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bigotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,9,2]]},"reference":[{"key":"33_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev.nu.16.070196.001315","volume":"16","author":"AL Olson","year":"1996","unstructured":"Olson AL, Pessin JE: Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr. 1996, 16: 235-256. 10.1146\/annurev.nu.16.070196.001315.","journal-title":"Annu Rev Nutr"},{"key":"33_CR2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/jnci\/94.14.1080","volume":"94","author":"S Ito","year":"2002","unstructured":"Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y, Kubota S: Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst. 2002, 94: 1080-1091.","journal-title":"J Natl Cancer Inst"},{"key":"33_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0090-4295(99)00474-4","volume":"55","author":"S Chang","year":"2000","unstructured":"Chang S, Lee S, Lee C, Kim JI, Kim Y: Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urol. 2000, 55: 448-452. 10.1016\/S0090-4295(99)00474-4.","journal-title":"Urol"},{"key":"33_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/hmg\/ddl032","volume":"15","author":"D Wang","year":"2006","unstructured":"Wang D, Pascual JM, Yang H, Engelstad K, Mao X, Cheng J, Yoo J, Noebels JL, De Vivo DC: A mouse model for Glut-1 haploinsufficiency. Hum Molecular Genet. 2006, 15: 1169-1179. 10.1093\/hmg\/ddl032.","journal-title":"Hum Molecular Genet"},{"key":"33_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF02904704","volume":"4","author":"M Grover-McKay","year":"1998","unstructured":"Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ: Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res. 1998, 4: 115-120.","journal-title":"Pathol Oncol Res"},{"key":"33_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.surg.2004.05.032","volume":"136","author":"H Ito","year":"2004","unstructured":"Ito H, Duxbury M, Zinner MJ, Ashley SW, Whang EE: Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004, 136: 548-556. 10.1016\/j.surg.2004.05.032.","journal-title":"Surgery"},{"issue":"4","key":"33_CR7","first-page":"928","volume":"7","author":"R Airley","year":"2001","unstructured":"Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001, 7 (4): 928-934.","journal-title":"Clin Cancer Res"},{"key":"33_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.pai.0000162003.43334.c7","volume":"14","author":"A Ashton-Sager","year":"2006","unstructured":"Ashton-Sager A, Paulino AF, Afify AM: GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol. 2006, 14: 187-192. 10.1097\/01.pai.0000162003.43334.c7.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"33_CR9","first-page":"437","volume":"11","author":"T Ito","year":"1998","unstructured":"Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H: Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol. 1998, 11: 437-443.","journal-title":"Mod Pathol"},{"key":"33_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/modpathol.3800732","volume":"20","author":"Y Kato","year":"2007","unstructured":"Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y: Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007, 20: 215-220. 10.1038\/modpathol.3800732.","journal-title":"Mod Pathol"},{"key":"33_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF02893436","volume":"13","author":"A Wincewicz","year":"2007","unstructured":"Wincewicz A, Sulkowska M, Koda M, Sulkowski S: Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer. Pathol Oncol Res. 2007, 13: 15-20.","journal-title":"Pathol Oncol Res"},{"key":"33_CR12","first-page":"1499","volume":"14","author":"M Yasuda","year":"2005","unstructured":"Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y: Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep. 2005, 14: 1499-1504.","journal-title":"Oncol Rep"},{"key":"33_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00259-005-0044-8","volume":"33","author":"U Tateishi","year":"2006","unstructured":"Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T: Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006, 33: 683-691. 10.1007\/s00259-005-0044-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"33_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.oraloncology.2006.10.009","volume":"43","author":"M Kunkel","year":"2007","unstructured":"Kunkel M, Moergel M, Stockinger M, Jeong JH, Fritz G, Lehr HA, Whiteside TL: Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol. 2007, 43: 796-803. 10.1016\/j.oraloncology.2006.10.009.","journal-title":"Oral Oncol"},{"key":"33_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0959-8049(00)00371-3","volume":"37","author":"M Sakashita","year":"2001","unstructured":"Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, Ichihara T, Kuroda Y, Maeda S, Kasuga M: Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001, 37: 204-209. 10.1016\/S0959-8049(00)00371-3.","journal-title":"Eur J Cancer"},{"key":"33_CR16","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1002\/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X","volume":"72","author":"RS Brown","year":"1993","unstructured":"Brown RS, Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993, 72: 2979-2985. 10.1002\/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X.","journal-title":"Cancer"},{"key":"33_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physiolgenomics.2001.5.1.21","volume":"5","author":"JM Markert","year":"2001","unstructured":"Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB, Benos DJ: Differential gene expression profiling in human brain tumors. Physiol Genomics. 2001, 5: 21-33.","journal-title":"Physiol Genomics"},{"key":"33_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0190-9622(97)70174-9","volume":"37","author":"SC Baer","year":"1997","unstructured":"Baer SC, Casaubon L, Younes M: Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J Am Acad Dermatol. 1997, 37: 575-577. 10.1016\/S0190-9622(97)70174-9.","journal-title":"J Am Acad Dermatol"},{"key":"33_CR19","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1016\/S0021-9258(18)77387-0","volume":"265","author":"TA Bird","year":"1990","unstructured":"Bird TA, Davies A, Baldwin SA, Saklatvala J: Interleukin 1 stimulates hexose transport in fibroblasts by increasing the expression of glucose transporters. J Biol Chem. 1990, 265: 13578-13583.","journal-title":"J Biol Chem"},{"key":"33_CR20","first-page":"1337","volume":"38","author":"T Higashi","year":"1997","unstructured":"Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotani R, Imamura M, Konishi J: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997, 38: 1337-1344.","journal-title":"J Nucl Med"},{"key":"33_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2006.08.018","volume":"55","author":"LF de Geus-Oei","year":"2007","unstructured":"de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC, Oyen WJ: Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007, 55: 79-87. 10.1016\/j.lungcan.2006.08.018.","journal-title":"Lung Cancer"},{"key":"33_CR22","first-page":"339","volume":"40","author":"JK Chung","year":"1999","unstructured":"Chung JK, Lee YJ, Kim C, Choi SR, Kim M, Lee K, Jeong JM, Lee DS, Jang JJ, Lee MC: Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med. 1999, 40: 339-346.","journal-title":"J Nucl Med"},{"key":"33_CR23","first-page":"22","volume":"45","author":"TC Yen","year":"2004","unstructured":"Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, Lin WJ, Chen JT, Chen WJ, Lai CR, Hsueh S: 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004, 45: 22-29.","journal-title":"J Nucl Med"},{"key":"33_CR24","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1007\/s10620-006-9428-2","volume":"51","author":"J Gu","year":"2006","unstructured":"Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, Tatsumi M, Sekimoto M, Hatazawa J, Nishimura T, Monden M: Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci. 2006, 51: 2198-2205. 10.1007\/s10620-006-9428-2.","journal-title":"Dig Dis Sci"},{"key":"33_CR25","first-page":"71","volume":"26","author":"E Minutilli","year":"2007","unstructured":"Minutilli E, Giannarelli D, Anz\u00e0 M, Garinei R, Perri P, Botti C, Piarulli L, Bruno P, Rea S, Visca P, Mottolese M, Di Filippo S, Di Filippo F: Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. J Exp Clin Cancer Res. 2007, 26: 71-76.","journal-title":"J Exp Clin Cancer Res"},{"key":"33_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00008390-200202000-00006","volume":"12","author":"PR Wachsberger","year":"2002","unstructured":"Wachsberger PR, Gressen EL, Bhala A, Bobyock SB, Storck C, Coss RA, Berd D, Leeper DB: Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. Melanoma Res. 2002, 12: 35-43. 10.1097\/00008390-200202000-00006.","journal-title":"Melanoma Res"},{"key":"33_CR27","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.1999.17.5.1508","volume":"17","author":"JD Wagner","year":"1999","unstructured":"Wagner JD, Schauwecker D, Davidson D, Coleman JJ, Saxman S, Hutchins G, Love C, Hayes JT: Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999, 17: 1508-1515.","journal-title":"J Clin Oncol"},{"key":"33_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00008390-200404000-00011","volume":"14","author":"AM Fink","year":"2004","unstructured":"Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A: Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004, 14: 141-145. 10.1097\/00008390-200404000-00011.","journal-title":"Melanoma Res"},{"key":"33_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1634\/theoncologist.7-4-271","volume":"7","author":"T Belhocine","year":"2002","unstructured":"Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P: Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist. 2002, 7: 271-278. 10.1634\/theoncologist.7-4-271.","journal-title":"Oncologist"},{"key":"33_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/CMR.0b013e32815c10b0","volume":"17","author":"E Maubec","year":"2007","unstructured":"Maubec E, Lumbroso J, Masson F, Suciu V, Kolb F, Mamelle G, Cavalcanti A, Boitier F, Spatz A, Aup\u00e9rin A, Leboulleux S, Avril MF: F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res. 2007, 17: 147-154. 10.1097\/CMR.0b013e32815c10b0.","journal-title":"Melanoma Res"},{"key":"33_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.humpath.2005.10.007","volume":"37","author":"CA Davies","year":"2006","unstructured":"Davies CA, Jeziorska M, Freemont AJ, Herrick AL: The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006, 37: 190-197. 10.1016\/j.humpath.2005.10.007.","journal-title":"Hum Pathol"},{"key":"33_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ijc.10904","volume":"104","author":"RE Airley","year":"2003","unstructured":"Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ: GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer. 2003, 104: 85-91. 10.1002\/ijc.10904.","journal-title":"Int J Cancer"},{"key":"33_CR33","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.humpath.2006.03.015","volume":"37","author":"MM Vleugel","year":"2006","unstructured":"Vleugel MM, Shvarts D, van der Wall E, van Diest PJ: p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum Pathol. 2006, 37: 1085-1092. 10.1016\/j.humpath.2006.03.015.","journal-title":"Hum Pathol"},{"key":"33_CR34","first-page":"6189","volume":"60","author":"DA Elson","year":"2000","unstructured":"Elson DA, Ryan HE, Snow JW, Johnson R, Arbeit JM: Coordinate up-regulation of hypoxia inducible factor (HIF)-1\u03b1 and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res. 2000, 60: 6189-6195.","journal-title":"Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-27-34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:30:49Z","timestamp":1630463449000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-27-34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-27-34","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"13 July 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"34"}}